Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive trial data for myelofibrosis treatment

Novartis reports positive trial data for myelofibrosis treatment

23rd December 2010

Novartis' investigational myelofibrosis treatment INC424 has demonstrated an encouraging performance in a phase III clinical trial.

During the recent Comfort-I study, the Janus kinase inhibitor therapy was shown to deliver a statistically significant reduction in spleen size compared to placebo, thereby meeting its primary efficacy endpoint.

Herve Hoppenot, president of Novartis Oncology, said: "Throughout its clinical development, INC424 has demonstrated the potential to fill a critical need for patients with myelofibrosis, who currently have limited treatment options."

The drug has been licensed by Novartis for international distribution outside the US and has received orphan drug status from American and European regulators.

Enrolment for a separate phase III trial, Comfort-II, was recently completed, with results set to be published in the first half of 2011.

Earlier this month, Novartis completed its takeover of eye care specialist Alcon, becoming a global leader in the sector in the process.ADNFCR-8000103-ID-800308876-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.